XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.24.3

Inventories | 9 Months Ended
--- | ---
Sep. 30, 2024
Inventory Disclosure [Abstract] |
Inventories | Inventories The principal categories of inventories were comprised of the following:
Inventory: |  | September 30, 2024 |  | December 31, 2023
Raw materials and supplies |  | $ | 4,048 |  |  | $ | 5,291 |
Work in process |  | 3,117 |  |  | 2,037 |
Finished goods |  | 8,932 |  |  | 3,052 |
Total |  | $ | 16,097 |  |  | $ | 10,380 |
The Company capitalizes inventory costs associated with products when future commercialization is considered probable and the future economic benefit is expected to be realized, which is typically when regulatory approval is obtained for a drug candidate. As such, the Company began capitalizing costs related to inventory in May 2023 upon FDA approval of LUMRYZ. Manufacturing costs associated with inventory purchased or produced prior to FDA approval were recorded as research and development expense in prior periods.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration